BreidenbachTKliemVBurgMRadermacherJHoffmanMWKlempnauerJ. Profound drop of cyclosporin A whole blood trough levels caused by St. Johns wort (Hypericum perforatum). Transplantation2000;69:2229–30.
2.
RobyCAAndersonGDKantorEDryerDABursteinAH. St. Johns wort: Effect on CYP3A4 activity. Clin Pharmacol Ther2000;67:451–7.
3.
MooreLBGoodwinBJonesSAWiselyGBSerabjit-SinghCJWillsonTMSt. Johns wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci2000;97:7500–2.
4.
GurleyBJGardnerSFHubbardMA. Clinical assessment of potential cytochrome P450–mediated herb– Drug interactions. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, Indianapolis, IN, October 28–November 2, 2000.
5.
De SmetPBrouwersJ. Pharmacokinetic evaluation of herbal remedies. Clin Pharmacokinet1997;32:427–36.
6.
ObermeierMTWhiteREYangCS. Effects of bioflavanoids on hepatic P450 activities. Xenobiotica1995;25:575–84.
7.
ZhaiSDaiRFriedmanFVestalR. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab Dispos1998;26:989–92.
8.
ReicksMMCrankshawDL. Modulation of rat hepatic cytochrome P- 450 activity by garlic organosulfur compounds. Nutr Cancer1996;25: 241–8.
9.
GurleyBJGardnerSFHubbardMA. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm2000;57:963–9.
10.
HahmHKujawaJAugsburgerL. Comparison of melatonin products against USPs supplement standards and other criteria. J Am Pharm Assoc1999;39:27–31.
11.
LibertiLEDer MaderosianA. Evaluation of commercial ginseng products. J Pharm Sci1978;67:1487–9.
12.
HeptinstallSAwangDVCDawsonBA. Parthenolide content and bio-activity of feverfew (Tanacetum parthenium). Estimation of commercial and authenticated products. J Pharm Pharmacol1992;44:391–5.
